๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for CLL/SLL

Registry of the German CLL Study Group NCT02863692n/a1 site๐Ÿ“ Dresden German CLL Study Group Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT03516617Phase 23 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Rochester Mayo Clinic ยท Tests: Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) NCT06136559Phase 3206 sites๐Ÿ“ Mobile๐Ÿ“ Gilbert๐Ÿ“ Phoenix Merck Sharp & Dohme LLC ยท Tests: Nemtabrutinib, Ibrutinib, Acalabrutinib Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial NCT05183854Phase 21 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites๐Ÿ“ La Jolla๐Ÿ“ Boston๐Ÿ“ Rochester AstraZeneca ยท Tests: AZD5492 A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) NCT04771507Phase 1, Phase 29 sites๐Ÿ“ Trondheim๐Ÿ“ Falun๐Ÿ“ Gรคvle Jeanette Lundin ยท Tests: Ibrutinib A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL NCT07609823Phase 21 site๐Ÿ“ Nanjing Guangzhou Lupeng Pharmaceutical Company LTD. ยท Tests: Lacutoclax Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Global Trial in APG2575 for Patients With CLL/SLL NCT06104566Phase 3135 sites๐Ÿ“ Tuscon๐Ÿ“ Anaheim๐Ÿ“ Jacksonville Ascentage Pharma Group Inc. ยท Tests: lisaftoclax +BTK inhibitor, BTK inhibitor Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Study on the Diagnosis and Management of CLL in Italy by GIMEMA NCT04867915n/a24 sites๐Ÿ“ Alessandria๐Ÿ“ Brescia๐Ÿ“ Brindisi Gruppo Italiano Malattie EMatologiche dell'Adulto Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: Exercise, Diet Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT07218341Phase 450 sites๐Ÿ“ Mobile๐Ÿ“ Tucson๐Ÿ“ Jacksonville Eli Lilly and Company ยท Tests: Pirtobrutinib, Idelalisib Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site๐Ÿ“ Bethesda National Heart, Lung, and Blood Institute (NHLBI) A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites๐Ÿ“ Phoenix๐Ÿ“ Duarte๐Ÿ“ Los Angeles Nurix Therapeutics, Inc. ยท Tests: NX-5948 A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. NCT06319456Phase 310 sites๐Ÿ“ Bengbu๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide๏ผŒCTX, Rituximab Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006Phase 1, Phase 26 sites๐Ÿ“ Aurora๐Ÿ“ Coral Gables๐Ÿ“ Eugene Nurix Therapeutics, Inc. ยท Tests: NX-5948, venetoclax, rituximab, obinutuzumab Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites๐Ÿ“ Orange๐Ÿ“ Denver๐Ÿ“ Coral Springs CSL Behring ยท Tests: IgPro20 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites๐Ÿ“ Duarte๐Ÿ“ Orange๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-2127 Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia NCT07061951Phase 29 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Sacramento National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06757647Phase 21 site๐Ÿ“ Columbus Seema Bhat ยท Tests: Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467Phase 211 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG2575 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Denver Vironexis Biotherapeutics Inc. ยท Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 The Pathogenesis and Prognostic Factors of Lymphoma NCT06203652n/a1 site๐Ÿ“ Shanghai Shanghai Zhongshan Hospital ยท Tests: Real-world regimen Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902Phase 3633 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites๐Ÿ“ Rochester๐Ÿ“ New York๐Ÿ“ Columbus Hoffmann-La Roche ยท Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Beijing BeOne Medicines ยท Tests: Tacabrutideg Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL NCT04494503Phase 1, Phase 218 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG-2575, Rituximab, Ibrutinib
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy